plasma plasminogen activator inhibitor-1 血浆纤溶酶原激活物抑制物
tissue plasminogen activator inhibitor 1 纤溶酶原激活物抑制剂
human plasminogen activator inhibitor 1 人纤溶酶原激活剂抑制物
tissue plasminogen activator inhibitor-1 组织型纤溶酶原激活物抑制物
Plasminogen activator inhibitor-1 deficiency 纤溶酶原激活物抑制剂
recombinant human plasminogen activator inhibitor-1 型纤溶酶原激活物抑制剂
plasminogen activator inhibitor type-1 纤溶酶原激活物抑制物 ; 型纤溶酶原激活物抑制剂
type 1 plasminogen activator inhibitor 纤溶酶原激活物抑制物
plasminogen activator inhibitor type 1-1 纤溶酶原激活物抑制物
Objective: To observe the expression changes of plasminogen activator inhibitor-1(PAI-1) and tissue inhibitor of metalloproteinase-1(TIMP-1) in kidney of diabetic nephropathy rats,and to explore the role of PAI-1 and TIMP-1 in the development of renal fibrosis of diabetic nephropathy(DP).
目的:动态观察纤溶酶原激活物抑制剂-1(PAI-1)和金属蛋白酶组织抑制因子-1(TIMP-1)在糖尿病大鼠肾脏中的表达,探讨PAI-1及TIMP-1在糖尿病肾病(DN)肾纤维化发生、发展过程中的作用。
参考来源 - 糖尿病大鼠肾脏PAI·2,447,543篇论文数据，部分数据来源于NoteExpress
以上来源于: WordNet
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。
Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
目的：探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素1的影响。
应用推荐